Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial..
Diabetes Obes Metab. 19(12), 1805-1809.
(2017). Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence..
Curr Vasc Pharmacol. 15(6), 599-606.
(2017). PATHWAY-2: spironolactone for resistant hypertension..
Lancet. 387(10026), 1372.
(2016). PATHWAY-2: spironolactone for resistant hypertension..
Lancet. 387(10026), 1371-1372.
(2016). Sleep EEG effects of anti-gluco- and anti-mineralocorticoids in old-aged men: pilot study..
Psychiatry Clin Neurosci. 68(5), 383-7.
(2014). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011). Spironolactone revisited..
J Clin Hypertens (Greenwich). 13(10), 783-4.
(2011).
(2010).
A comparison of the aldosterone-blocking agents eplerenone and spironolactone..
Clin Cardiol. 32(4), 230.
(2009). Spironolactone increases permeability of visceral sheep peritoneum..
Adv Perit Dial. 25, 16-9.
(2009). Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study..
Lancet. 371(9628), 1921-6.
(2008). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism..
Nephrol Dial Transplant. 22(1), 293.
(2007). Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient..
QJM. 98(12), 913-5.
(2005).